Literature DB >> 18397322

Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization.

Nicole Müller1, Agnes Wyzgol, Sabine Münkel, Klaus Pfizenmaier, Harald Wajant.   

Abstract

OX40 ligand (OX40L) and OX40 are typical members of the tumor necrosis factor ligand family and the tumor necrosis factor receptor superfamily, respectively, and are involved in the costimulation and differentiation of T cells. Like other tumor necrosis factor ligands, OX40L is a type II transmembrane protein. Recombinant soluble human OX40L assembles into trimers and is practically inactive despite binding to OX40. However, oligomerization of soluble OX40L trimers by cross-linking with antibodies or by expression as a hexameric fusion protein strongly increased the activity of the ligand. Moreover, a fusion protein of OX40L with a single chain fragment recognizing the tumor stroma antigen fibroblast activation protein showed a cell surface antigen-dependent increase in the activity of the ligand domain of the molecule and thus mimicked the activity of membrane OX40L upon antigen binding. Trimeric single chain OX40L fusion proteins therefore represent a novel type of OX40L-derived immunostimulatory molecule with potentially reduced systemic side effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18397322     DOI: 10.1111/j.1742-4658.2008.06382.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  12 in total

1.  The tumor necrosis factor receptor stalk regions define responsiveness to soluble versus membrane-bound ligand.

Authors:  Christine Richter; Sylvia Messerschmidt; Gerlinde Holeiter; Jessica Tepperink; Sylvia Osswald; Andrea Zappe; Marcus Branschädel; Verena Boschert; Derek A Mann; Peter Scheurich; Anja Krippner-Heidenreich
Journal:  Mol Cell Biol       Date:  2012-04-30       Impact factor: 4.272

2.  Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells.

Authors:  Isabell Lang; Simone Füllsack; Agnes Wyzgol; Andrea Fick; Johannes Trebing; José Antonio Carmona Arana; Viktoria Schäfer; Daniela Weisenberger; Harald Wajant
Journal:  J Biol Chem       Date:  2015-12-31       Impact factor: 5.157

Review 3.  Control of immunity by the TNFR-related molecule OX40 (CD134).

Authors:  Michael Croft
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

Review 4.  The role of TNF superfamily members in T-cell function and diseases.

Authors:  Michael Croft
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

5.  Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2).

Authors:  Hilka Rauert; Andreas Wicovsky; Nicole Müller; Daniela Siegmund; Volker Spindler; Jens Waschke; Christian Kneitz; Harald Wajant
Journal:  J Biol Chem       Date:  2009-12-28       Impact factor: 5.157

Review 6.  Principles of antibody-mediated TNF receptor activation.

Authors:  H Wajant
Journal:  Cell Death Differ       Date:  2015-08-21       Impact factor: 15.828

7.  Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2.

Authors:  Roman Fischer; Jessica Marsal; Cristiano Guttà; Stephan A Eisler; Nathalie Peters; John R Bethea; Klaus Pfizenmaier; Roland E Kontermann
Journal:  Sci Rep       Date:  2017-07-26       Impact factor: 4.379

8.  Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.

Authors:  Edwin Bremer
Journal:  ISRN Oncol       Date:  2013-06-11

9.  Regulation of PI-3-Kinase and Akt Signaling in T Lymphocytes and Other Cells by TNFR Family Molecules.

Authors:  Takanori So; Michael Croft
Journal:  Front Immunol       Date:  2013-06-07       Impact factor: 7.561

10.  Natural OX40L expressed on human T cell leukemia virus type-I-immortalized T cell lines interferes with infection of activated peripheral blood mononuclear cells by CCR5-utilizing human immunodeficiency virus.

Authors:  Daigo Kasahara; Azusa Takara; Yoshiaki Takahashi; Akira Kodama; Reiko Tanaka; Aftab A Ansari; Yuetsu Tanaka
Journal:  Virol J       Date:  2013-11-18       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.